During this period provided a broad range of services to multiple companies. These consulting services related to activities including, but not limited to; FDA interactions, business development and licensing, venture capital, drug development, investment banking due diligence, company formation, and general strategy/corporate development. A broad range of therapeutic areas were involved, with a focus on oncology and ophthalmology. Clients included multi-national publically traded… Show more During this period provided a broad range of services to multiple companies. These consulting services related to activities including, but not limited to; FDA interactions, business development and licensing, venture capital, drug development, investment banking due diligence, company formation, and general strategy/corporate development. A broad range of therapeutic areas were involved, with a focus on oncology and ophthalmology. Clients included multi-national publically traded companies, small private start-up companies and an investment banking firm. The following are specific examples:(1) Provide general drug development, licensing, venture capital and corporate formation assistance to a private clinical stage oncology company. Transformed the company from the preclinical stage, by the acquisition/license of assets from a global top tier pharmaceutical company, to one preparing to initiate Phase 2 clinical trials. On the Board of Directors until 2017.(2) Provide general drug development consulting to a private clinical stage company developing a novel class of pharmaceuticals for a wide variety of therapeutic indications, including but not limited to numerous ophthalmic and oncology diseases. Specific involvement included clinical trials, FDA interactions, toxicology, pharmacokinetics and formulation development. (3) Co-Founding an ophthalmic company based on a new and disruptive technology. This activity has included development of total drug development plans, a business plan and a capital raising strategy/document package. Accepted the position of Chief Executive Officer and Board of Directors in September 2016. (4) Provided due diligence activities to investment banks assessing new potential fund opportunities in the fields of pharmaceuticals and devices. Show less

Icon Bioscience, Inc. (IBI) is a privately held company focused on the development and commercialization of novel ophthalmic pharmaceuticals, based on its proprietary drug delivery platform technology. Icon Bioscience was acquired by Psivida in 2018. A product portfolio was developed targeting major ophthalmic markets including glaucoma, “wet” age-related macular degeneration, “dry” age-related macular degeneration, cataract surgery, retinoblastoma, macular edema and diabetic retinopathy.… Show more Icon Bioscience, Inc. (IBI) is a privately held company focused on the development and commercialization of novel ophthalmic pharmaceuticals, based on its proprietary drug delivery platform technology. Icon Bioscience was acquired by Psivida in 2018. A product portfolio was developed targeting major ophthalmic markets including glaucoma, “wet” age-related macular degeneration, “dry” age-related macular degeneration, cataract surgery, retinoblastoma, macular edema and diabetic retinopathy. Key accomplishments/responsibilities include:• Developed a product portfolio consisting of 8 proprietary products based on a novel technology. Two products in clinical trials with most advanced (Dexycu) completing a pivotal Phase 2/3 clinical trial. Second Phase 2/3 clinical trial initiated. Dexycu is FDA approved.• Assisted in raising $10+ million financing round. Raised $6 million Series A financing round.• Raised $16 million venture capital institution-led Series B financing round with 40% valuation increase. • Generated acquisition offer for company that represented a 700% increase in value relative to the financing investment. • Executed multiple research collaboration and partnership agreements with global pharmaceutical companies.• Developed global development and commercialization strategy. • Developed and managed a multi-tier international intellectual property plan. • Executed an agreement with a major academic healthcare institution for the development and commercialization of an Orphan Drug. Obtained FDA approval of official Orphan Drug Designation. Show less

The University of Alabama at Birmingham Research Foundation is the entity responsible for the commercialization of technology derived from the university’s research. UAB is an internationally known academic center, consistently ranked in the top tier of NIH-funded institutions. This position has overall management responsibility for the organization. Key accomplishments include:• Doubling revenue of organization in each year, far exceeding budgets • Rebuilding and restructuring… Show more The University of Alabama at Birmingham Research Foundation is the entity responsible for the commercialization of technology derived from the university’s research. UAB is an internationally known academic center, consistently ranked in the top tier of NIH-funded institutions. This position has overall management responsibility for the organization. Key accomplishments include:• Doubling revenue of organization in each year, far exceeding budgets • Rebuilding and restructuring of entire organization concurrent with resolving intellectual property backlog (1000+). • Creation and management of UAB Concept Fund, an early-stage venture fund for UAB • Served as Director on boards of multiple organizations including SE BIO, the Birmingham Venture Club and the technology incubator. • Execution of license, option, and business start-up agreements • Management of multi-million dollar licensing and research corporate partnerships• Management and settlement of multiple litigation matters Show less

BioCache Pharmaceuticals, Inc. (BioCache) was an early-stage biotechnology company focused on the development and commercialization of novel, proprietary biopharmaceuticals. BioCache’s initial product candidates targeted a variety of therapeutic areas including oncology, infectious and cardiovascular disease. This position had overall management responsibility for the organization as it sought to transition from an academic setting with a basic research approach, to a commercially-driven… Show more BioCache Pharmaceuticals, Inc. (BioCache) was an early-stage biotechnology company focused on the development and commercialization of novel, proprietary biopharmaceuticals. BioCache’s initial product candidates targeted a variety of therapeutic areas including oncology, infectious and cardiovascular disease. This position had overall management responsibility for the organization as it sought to transition from an academic setting with a basic research approach, to a commercially-driven entity backed with institutional level funding. Accomplishments:• Restructured programs for a commercially viable pharmaceutical organization including overall business plan, intellectual property program and employee benefits.• Closing of 3 separate financing rounds of angel and private equity during a 12-month period.• Identified, negotiated terms, and executed agreement with investment banking firm to facilitate pursuit of institutional round of financing.• Identified, negotiated terms, and executed agreement with venture capital firm to syndicate a Series A financing round.• External research collaborations initiated with leading academic centers. Show less

Monsanto Pharma Technologies was responsible for creating and developing new life science-based business units associated with the pharmaceutical industry. The initial Business Leader position had overall responsibility for the commercial/technical evaluation of opportunities in the earliest stages of development or concept identification. The scope of these businesses ranged from unique drug delivery technologies, to concepts specifically targeting developing economies in Eastern Europe and… Show more Monsanto Pharma Technologies was responsible for creating and developing new life science-based business units associated with the pharmaceutical industry. The initial Business Leader position had overall responsibility for the commercial/technical evaluation of opportunities in the earliest stages of development or concept identification. The scope of these businesses ranged from unique drug delivery technologies, to concepts specifically targeting developing economies in Eastern Europe and Asia, to a variety of entrepreneurial biotechnology-based opportunities. The President position began in December 1998 with the formal creation of Integrated Protein Technologies. This business was selected as the prime example of how Monsanto's core life sciences concept was capable of delivering revolutionary advances to global health care. Accomplishments:• Direct management responsibility for the creation of an organization with a $400-500 million valuation in less than two years. • Development and implementation of initial business plan for creation of a new life sciences business combining pharmaceutical and plant biotechnology for application in the pharmaceutical industry for the first time.• Management of initial sales and marketing effort promoting the capabilities of plants to express therapeutic proteins, yielding significant licensing contracts within the first year.• Management of operations which produced the first therapeutic protein expressed in transgenic plants to be administered in humans.• Ongoing creation of the business infrastructure necessary to support a new business as it evolved from an early feasibility stage to global commercial capabilities, including the acquisition or licensing of necessary ancillary intellectual property.• Negotiated $20+ million incentive package from a state seeking to attract the company, including over $18 million in research funding in addition to standard incentives. Show less

Storz Ophthalmics Division had annual sales of $250 million. Developing and marketing both pharmaceuticals and medical devices, Storz was a global organization focused on ophthalmology. This position was responsible for corporate development/licensing, strategic planning and marketing research on a global basis for the entire division, pharmaceuticals and medical devices. Pharmaceutical R&D was also directed by this position. Accomplishments:• Served as member of Management… Show more Storz Ophthalmics Division had annual sales of $250 million. Developing and marketing both pharmaceuticals and medical devices, Storz was a global organization focused on ophthalmology. This position was responsible for corporate development/licensing, strategic planning and marketing research on a global basis for the entire division, pharmaceuticals and medical devices. Pharmaceutical R&D was also directed by this position. Accomplishments:• Served as member of Management Committee.• Development and implementation of the initial long-term business plan toward the corporate development of a technology-driven pharmaceutical business• Identification, evaluation and license of exclusive worldwide rights to cidofovir. Direction of global development program using internal and external resources, including selection of and out-licensing to partner in Japan. Cidofovir, a nucleotide analog, was developed as the first broad spectrum anti-viral, specifically targeting herpes and adenoviral infections.• Option/License of U.S. and European rights to novel therapeutic agent from Japanese firm• Responsible for the initial identification and evaluation of a business merger opportunity which ultimately led to a $600 million acquisition of two separate organizations and the creation of a new global leader in the ophthalmic field.• Identification, evaluation and acquisition of access to a proprietary drug delivery technology targeting a broad range of potential ophthalmic applications. Show less